Here are 1-2 brief analogies to describe Inspire Medical Systems (INSP):

• Like a specialized Medtronic focused on treating sleep apnea.
• The Cochlear Limited of sleep apnea treatment.

• Inspire system: A neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea (OSA).
• Novel closed-loop solution: A developing technology designed to continuously monitor a patient's breathing and deliver mild hypoglossal nerve stimulation to maintain an open airway.

Inspire Medical Systems (INSP) sells its Inspire system primarily to healthcare providers and facilities, which then use the technology to treat individual patients with obstructive sleep apnea (OSA).

The major categories of customers for Inspire Medical Systems are:

1. Hospitals: Large medical institutions that perform a wide range of surgical procedures and treatments, including those for sleep disorders.
2. Ambulatory Surgical Centers (ASCs): Facilities where surgical procedures that do not require an overnight hospital stay are performed, often offering a more cost-effective setting for device implantation.
3. Specialized ENT (Ear, Nose, and Throat) Practices and Sleep Clinics: Medical practices and centers that specialize in the diagnosis and treatment of conditions related to the ear, nose, throat, and sleep disorders, where Inspire system implantations are performed.

Timothy P. Herbert, Chairman, President and Chief Executive Officer

Mr. Herbert is the founder of Inspire Medical Systems, establishing the company in 2007. He has served as President and CEO since its inception and assumed the role of Chairman of the Board in May 2024. Before founding Inspire, Mr. Herbert spent 11 years, from 1996 to 2007, at Medtronic plc, where he held various management positions across product development, clinical research, sales, marketing, and healthcare reimbursement. He was instrumental in developing Inspire's core neurostimulation technology and leading its capital formation strategies. Mr. Herbert holds a B.S. in Electrical Engineering from North Dakota State University and an M.B.A. from the University of St. Thomas.

Matt Osberg, Executive Vice President and Chief Financial Officer

Mr. Osberg was appointed Executive Vice President and Chief Financial Officer, effective January 19, 2026. He brings over 20 years of experience in financial leadership. Prior to joining Inspire, Mr. Osberg served as Executive Vice President and CFO at Apogee Enterprises, Inc. His career also includes CFO positions at Helen of Troy, Ltd. and various finance leadership roles at Best Buy, Inc. He began his career at Ernst & Young LLP. Mr. Osberg has a background primarily outside of the medical technology industry.

Bryan K. Phillips, SVP, General Counsel, Chief Compliance Officer and Corporate Secretary

Mr. Phillips joined Inspire Medical Systems in January 2021. Before his role at Inspire, he served as Chief Legal Officer at Cerevel Therapeutics Holdings, Inc. from 2019 to 2021. He also spent 14 years at Surmodics, Inc., a publicly traded medical technology company, holding various positions including Senior Vice President, Legal and Human Resources, General Counsel, and Secretary. Earlier in his career, he was patent counsel at Guidant Corporation's Cardiac Rhythm Management Group (now part of Boston Scientific) and began his legal career at a Minneapolis-based intellectual property law firm. Mr. Phillips holds a B.S. in Mechanical Engineering from the University of Kansas and a J.D. from the University of Minnesota Law School.

Carlton W. Weatherby, Chief Strategy and Growth Officer

Mr. Weatherby has been Inspire Medical Systems' Chief Strategy and Growth Officer since January 2024. Prior to joining Inspire, he served as the Chief Commercial Officer at AliveCor, Inc., a medical device company, from July 2021 to December 2023. He also held roles as President, Commercial Operations, and Chief Commercial Officer at Intersect ENT, Inc., a medical technology company, from October 2017 to July 2021, and as Vice President, Sales & Marketing, ENT at Smith & Nephew plc from January 2013 to October 2017. Mr. Weatherby received his B.S. in Biology from West Chester University.

John C. Rondoni, Chief Product & Innovation Officer

Mr. Rondoni has served as Inspire Medical Systems' Chief Product & Innovation Officer since January 2025. He has been with Inspire since January 2010, holding various positions including Vice President of Product Development, Operations & Quality. Before joining Inspire, Mr. Rondoni spent 11 years at Medtronic, Inc., where he held leadership roles in research and development. He began his career at Boston Scientific, Inc. in research and development. Mr. Rondoni holds a B.S. in Bioengineering from Syracuse University and an M.S. in Biomedical Engineering from the University of Alabama, Birmingham.

The key risks to Inspire Medical Systems (INSP) primarily revolve around reimbursement challenges, increasing competition, and operational hurdles related to product launches.

1. Reimbursement Uncertainty and Operational Challenges with New Product Launches: Inspire Medical Systems faces significant risks due to evolving and uncertain reimbursement policies, particularly concerning its latest device, Inspire V. There have been issues with CMS coding, including a shift from CPT code 64568 to 64582, which could reduce professional fees. A notable concern was the reversal of a key Medicare reimbursement code by administrative contractors, which negatively impacted reimbursement rates and created uncertainty about future revenue growth. Furthermore, the company is facing securities fraud lawsuits alleging that it concealed critical operational failures during the Inspire V launch, such as incomplete training and onboarding for treatment centers, delays in software updates for Medicare claims processing, and an excess inventory of the older Inspire IV device, all of which led to a significant reduction in 2025 earnings guidance.

2. Increasing Competition from Alternative Therapies and Competitors: The market for obstructive sleep apnea (OSA) treatment is becoming more competitive. Inspire faces competition from established players like ResMed, which dominates the CPAP machine market (the standard first-line treatment for OSA). Moreover, emerging alternative therapies pose a threat, including oral appliance therapies, new pharmaceutical treatments like GLP-1 drugs (e.g., Lilly's Tirzepatide, which can improve sleep quality in obese patients), and Apnimed's AD109. These alternatives could potentially dilute Inspire's market opportunity, especially for its third-line treatment offering.

3. Healthcare Provider Capacity Constraints: The growth and adoption of Inspire's hypoglossal nerve stimulation therapy are heavily reliant on ear, nose, and throat (ENT) surgeons who perform the implantation procedures. A potential constraint on the company's growth is the capacity of the ENT workforce. If the growth in the number of ENT surgeons or their availability to perform these procedures does not keep pace with the demand for Inspire's device, it could cap the company's growth potential.

The emergence of competing hypoglossal nerve stimulation devices represents a clear emerging threat. Specifically, Nyxoah's Genio system, which received FDA approval in August 2023, is a direct competitor to Inspire's core technology. Nyxoah's system is also designed for obstructive sleep apnea and offers a battery-free, leadless, and minimally invasive solution, which could differentiate it in the market and challenge Inspire's market share and first-mover advantage.

Inspire Medical Systems (INSP) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

1. Successful launch and adoption of new product generations: The company anticipates continued revenue growth from the successful launch and strong acceptance of its fifth-generation Inspire V system, which was a significant contributor to revenue in late 2025 and is expected to fuel momentum in 2026.
2. Increased utilization at existing implanting centers: A primary driver of U.S. revenue growth has been, and is expected to continue to be, higher utilization of the Inspire therapy at already established medical centers.
3. Expansion of implanting centers and sales territories: Inspire Medical Systems consistently focuses on activating new U.S. medical centers and expanding its sales organization by creating new sales territories, thereby increasing market penetration and access to its therapy.
4. Direct-to-consumer marketing programs: The company's ongoing direct-to-consumer marketing initiatives are expected to continue raising awareness and driving patient interest, contributing to overall demand and revenue growth.
5. Potential positive reimbursement developments: Inspire Medical Systems sees potential upside from ongoing reimbursement developments, although these have not yet been fully factored into current growth forecasts. Recent clarifications regarding CPT codes for the Inspire V procedure could influence future revenue.

Share Repurchases

• Inspire Medical Systems' Board of Directors authorized a share repurchase program of up to $200 million on August 11, 2025, which is set to expire on August 7, 2027.
• In 2025, the company completed $175 million in share repurchases.
• Previously, on August 6, 2024, the Board authorized the repurchase of up to $150 million of common stock, a program that was the first of its kind for Inspire and set to expire on August 5, 2026.

Share Issuance

• As of April 30, 2025, Inspire Medical Systems had 29,493,924 shares of common stock outstanding.
• For 2026, the estimated weighted average diluted shares outstanding are approximately 29.4 million.
• In February 2026, an executive acquired 2,196 shares through vested performance stock units, and another officer acquired 2,400 shares from similar vested units, along with 15,958 additional shares via a new stock award.

Capital Expenditures

• For the upcoming year, 2026, Inspire Medical Systems anticipates capital expenditures to range between $45 million and $50 million.
• The company made significant investments in 2025 to build its commercial infrastructure, increase patient marketing, and expand medical education expenses, particularly to support the U.S. launch of its Inspire V neurostimulation system.